Experienced board member, Chief Financial Officer and strategic consultant Gary Sender joins board of directors to Chair the Finance Committee Both appointments precede multiple value-creating ...

Merck gains preclinical compounds designed to exploit DNA repair defects in difficult to treat cancersNEW HAVEN, Conn., Oct.

Merck & Co. is putting down $30 million cash to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset ...

Berenberg Bank analyst Luisa Hector maintained a Buy rating on Merck & Company (MRK – Research Report) yesterday and set a price ...

Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of ...

TIME convened the first-ever TIME100 Health Leadership Forum to bring together individuals driving innovation and creating ...

Boston has become world-famous for its booming biotech industry. Over the past 20 years, the city has been buzzing with ...

Zacks Research lowered their Q3 2024 earnings estimates for Merck & Co., Inc. in a report issued on Monday, October 21st.

Empowering young women with the confidence to excel in their education is key to inspiring the next generation' ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...

Immutep (ASX:IMM) has made significant progress over the past year with its lead immunotherapy candidate, eftilagimod alpha ...